Kinevant Sciences is developing new therapies for rare inflammatory and autoimmune diseases. Cytokines are small proteins that regulate the immune system and play a role in driving many inflammatory diseases. Many cytokines are already validated as targets for treating inflammatory diseases, and Kinevant is further expanding the potential. Kinevant’s lead candidate, namilumab, is a novel monoclonal antibody being developed for pulmonary sarcoidosis treatment. Namilumab targets a key pro-inflammatory cytokine involved in the disease, GM-CSF, and has been demonstrated to be well-tolerated in multiple clinical trials. Plans are in place to start Phase 2 trials in patients soon.

<p>Kinevant Sciences is developing new therapies for rare inflammatory and autoimmune diseases. Cytokines are small proteins that regulate the immune system and play a role in driving many inflammatory diseases. Many cytokines are already validated as targets for treating inflammatory diseases, and Kinevant is further expanding the potential. Kinevant’s lead candidate, namilumab, is a novel monoclonal antibody being developed for pulmonary sarcoidosis treatment. Namilumab targets a key pro-inflammatory cytokine involved in the disease, GM-CSF, and has been demonstrated to be well-tolerated in multiple clinical trials. Plans are in place to start Phase 2 trials in patients soon.</p>


Kinevant Sciences

Short description:

Drug notes:

Long description:

Jobs: